Invitation to presentation of BioArctic s Full Year Report for the period January - December 2020 on February 4 at 9.30 a.m. CET
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B)
will publish the company s Full Year Report for the period January - December 2020 on
Thursday, February 4, 2021, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on February 4, at 09:30 CET, where Gunilla Osswald, CEO, and Jan Mattsson, CFO, will present BioArctic and comment on the Full Year Report for the period January - December 2020, followed by a Q&A-session.
To attend, please dial-in at one of the numbers below, from:
BioArctic receives European patent for new antibodies targeting Alzheimer s disease
STOCKHOLM, Jan. 27, 2021 /PRNewswire/
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer s disease. The antibodies target a shorter (truncated) form of amyloid beta (pE3-Aß) and are linked to the company s project AD1503. The patent enters into force on 27 January 2021 and expires in 2030.
BioArctic s newly granted patent focuses on novel antibodies which target pE3-Ab, a specific truncated form of amyloid beta. Monomers of pE3-Ab are highly prone to aggregate, leading to the formation of harmful soluble Ab aggregates which cause debilitating cognitive and other symptoms in Alzheimer s disease.
- Patent protection until 2039 - Previous human pharmacokinetic (PK) study showed significantly better PK profile when compared to market leading product UPPSALA, Sweden, Jan. 27,
/PRNewswire/ BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company s Full Year Report for the period January - December 2020 on Thursday,.
Orexo announces new US patent for ZUBSOLV®
News provided by
Share this article
UPPSALA, Sweden, Dec. 30, 2020 /PRNewswire/ Orexo AB (publ.),
(STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV®, Orexo s sublingual buprenorphine and naloxone tablet (CII) for the treatment of opioid use disorder.
The new patent, US Patent No. 10,874,661, expires in September 2032 and further strengthens the company s intellectual property for ZUBSOLV® in the US. Orexo will now have six patents listed in the Orange Book for ZUBSOLV®.
Nikolaj Sørensen, President and CEO, said: I am pleased to announce that we have further enhanced our patent protection of ZUBSOLV® with a new patent granted in the US. Strong patent protection is the foundation on which we finance and develop new innovative products to the benefit of patients and society. We continue to obtain strong patent protection of our products,